Breaking Finance News

Flexion Therapeutics Inc (NASDAQ:FLXN) has been upgraded to Hold in a statement by ValuEngine earlier today.

Just yesterday Flexion Therapeutics Inc (NASDAQ:FLXN) traded 2.28% higher at $19.52. FLXN’s 50-day average is $23.28 and its two hundred day average is $21.96. With the last close down 8.33% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the date range. Trading volume was down over the average, with 450,252 shares of FLXN changing hands under the typical 550,245

ValuEngine has upgraded Flexion Therapeutics Inc (NASDAQ:FLXN) to Hold in a report released on 6/21/2017.

Recent Performance Chart

Flexion Therapeutics Inc (NASDAQ:FLXN)

Flexion Therapeutics Inc has a with a one year low of $15.75 and a 52 week high of $29.41 Flexion Therapeutics Inc’s market capitalization is currently $0.

Also covering Flexion Therapeutics Inc's price target, a total of 7 equity analysts have released a ratings update on FLXN. The one year target is $35.71 with two analysts rating the stock a strong buy, 5 firms rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Company Details For Flexion Therapeutics Inc (NASDAQ:FLXN)

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.